Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations

Lung Cancer

Volumn 70, Issue 1, 2010, Pages 94-102

  Hiramatsu, Miyako ^a,b   Ninomiya, Hironori ^a   Inamura, Kentaro ^a   Nomura, Kimie ^a   Takeuchi, Kengo ^a   Satoh, Yukitoshi ^a,c   Okumura, Sakae ^c   Nakagawa, Ken ^c   Yamori, Takao ^c   Matsuura, Masaaki ^a   Morikawa, Toshiaki ^b   Ishikawa, Yuichi ^a  

^a CANCER INSTITUTE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Akt; Lung adenocarcinoma; Receptor tyrosine kinases; Signal pathway; Survival; TTF 1

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; THYROID TRANSCRIPTION FACTOR 1;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; EGFR GENE; ENZYME ACTIVATION; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMOKING;

ADENOCARCINOMA; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENES, ERBB-1; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77956187967     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.01.001     Document Type: Article

References (43)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21:2237-2246. [corrected].
3. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
4. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
5. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22:153-183.
6. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997, 9:180-186.
7. Testa J.R., Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001, 98:10983-10985.
8. Burgering B.M., Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376:599-602.
9. Virtanen C., Ishikawa Y., Honjoh D., Kimura M., Shimane M., Miyoshi T., et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci USA 2002, 99:12357-12362.
10. International Union Against Cancer: TNM classification of malignant tumors 1997, 91-97. Wiley-Liss, New York, NY. 5th ed. L.H. Sobin, C. Wittekind (Eds.).
11. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology and genetics of tumours of lung, pleura, thymus and heart 2004, IARC, Lyon, France.
12. Yamori T., Matsunaga A., Sato S., Yamazaki K., Komi A., Ishizu K., et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999, 59:4042-4049.
13. Team RDC R: a language and environment for statistical computing 2007, Available from http://www.R-project.org.
14. Tang J.M., He Q.Y., Guo R.X., Chang X.J. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006, 51:181-191.
15. Uddin S., Hussain A.R., Siraj A.K., Manogaran P.S., Al-Jomah N.A., Moorji A., et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186.
16. Chadha K.S., Khoury T., Yu J., Black J.D., Gibbs J.F., Kuvshinoff B.W., et al. Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 2006, 13:933-939.
17. Kobayashi I., Semba S., Matsuda Y., Kuroda Y., Yokozaki H. Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma. Pathobiology 2006, 73:8-17.
18. Lin H.J., Hsieh F.C., Song H., Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 2005, 93:1372-1381.
19. Kim T.J., Lee J.W., Song S.Y., Choi J.J., Choi C.H., Kim B.G., et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 2006, 94:1678-1682.
20. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
21. Manning B.D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004, 167:399-403.
22. Balsara B.R., Pei J., Mitsuuchi Y., Page R., Klein-Szanto A., Wang H., et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004, 25:2053-2059.
23. Bose S., Chandran S., Mirocha J.M., Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006, 19:238-245.
24. Dobashi Y., Suzuki S., Matsubara H., Kimura M., Endo S., Ooi A. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 2009, 115:107-118.
25. Yatabe Y., Kosaka T., Takahashi T., Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005, 29:633-639.
26. Tanaka H., Yanagisawa K., Shinjo K., Taguchi A., Maeno K., Tomida S., et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007, 67:6007-6011.
27. Iwagaki A., Choe N., Li Y., Hemenway D.R., Kagan E. Asbestos inhalation induces tyrosine nitration associated with extracellular signal-regulated kinase 1/2 activation in the rat lung. Am J Respir Cell Mol Biol 2003, 28:51-60.
28. Yoshida K., Kuwano K., Hagimoto N., Watanabe K., Matsuba T., Fujita M., et al. MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol 2002, 198:388-396.
29. Farivar A.S., Woolley S.M., Fraga C.H., Byrne K., Mulligan M.S. Proinflammatory response of alveolar type II pneumocytes to in vitro hypoxia and reoxygenation. Am J Transpl 2004, 4:346-351.
30. Murphy L.O., Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006, 31:268-275.
31. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995, 80:179-185.
32. Cox A.D., Der C.J. The dark side of Ras: regulation of apoptosis. Oncogene 2003, 22:8999-9006.
33. Shields J.M., Pruitt K., McFall A., Shaub A., Der C.J. Understanding Ras: it ain't over 'til it's over. Trends Cell Biol 2000, 10:147-154.
34. Sun P., Watanabe H., Takano K., Yokoyama T., Fujisawa J., Endo T. Sustained activation of M-Ras induced by nerve growth factor is essential for neuronal differentiation of PC12 cells. Genes Cells 2006, 11:1097-1113.
35. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
36. Sarkaria I.S., Zakowski M.F., Pham D., Hezel M., Ebright M.I., Chuai S., et al. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. Ann Thorac Surg 2008, 85:216-223.
37. Devereux T.R., Holliday W., Anna C., Ress N., Roycroft J., Sills R.C. Map kinase activation correlates with K-ras mutation and loss of heterozygosity on chromosome 6 in alveolar bronchiolar carcinomas from B6C3F1 mice exposed to vanadium pentoxide for 2 years. Carcinogenesis 2002, 23:1737-1743.
38. Schmitz K.J., Wohlschlaeger J., Alakus H., Bohr J., Stauder M.A., Worm K., et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch 2006.
39. Ji H., Wang Z., Perera S.A., Li D., Liang M.C., Zaghlul S., et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007, 67:4933-4939.
40. Conde E., Angulo B., Tang M., Morente M., Torres-Lanzas J., Lopez-Encuentra A., et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 2006, 12:710-717.
41. Pullen N., Dennis P.B., Andjelkovic M., Dufner A., Kozma S.C., Hemmings B.A., et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998, 279:707-710.
42. Pearson R.B., Thomas G. Regulation of p70s6k/p85s6k and its role in the cell cycle. Prog Cell Cycle Res 1995, 1:21-32.
43. Yaguchi S., Fukui Y., Koshimizu I., Yoshimi H., Matsuno T., Gouda H., et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006, 98:545-556.